COMPANY:

Freenome

"Freenome...announced...it has acquired Oncimmune Ltd...with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures...The acquisition of Oncimmune Ltd provides Freenome with clinical and commercial resources to complement Freenome’s frontline screening efforts."

"Freenome...announced...that the Institute for Population and Precision Health (IPPH) at the University of Chicago has joined as a study partner for its Vallania Study. The Vallania Study began enrollment in 2022 and focuses on the detection of multiple cancers...The Vallania Study is a key milestone in Freenome’s plan to expand early detection of cancer screening beyond colorectal cancer (CRC). Last year, the company completed enrollment for PREEMPT CRC, its validation study for the detection of CRC."

"Freenome...announced...that Renown Health has joined as a partner for the Sanderson Study, Freenome’s study of its multiomics platform, in combination with real-world data to detect multiple cancers...The study encompasses both traditional and real-world data to generate evidence of clinical validation for certain high- and elevated-risk populations while also refining the platform’s cancer classification and risk prediction models. In addition, the Sanderson Study will build the necessary infrastructure to bridge the gap between clinical research and day-to-day clinical impact."

"Freenome...presents a subject population analysis from PREEMPT CRC, a study for the detection of colorectal cancer (CRC) at the Western Colorectal Cancer Consortium Conference in Portland, Oregon...PREEMPT CRC is the largest prospective study for CRC using a blood-based screening test in the average-risk population and is Freenome’s clinical validation study for the use of its test."

"Oncimmune Holdings PLC on Friday said that it has collaborated with Siemens Healthineers AG, a Frankfurt-based medical technology company, in order to improve malignancy risk assessment in lung cancer....The collaboration will bring together Oncimmune's EarlyCDT Lung blood test with Siemens Healthineers' AI-Rad Companion Chest CT, an AI-powered radiology assistant that supports radiologists by performing automatic post-processing, quantifying and interpreting data....The collaboration will access data from the Early Detection of Cancer of the Lung Scotland trial, the large randomised study into the utility of EarlyCDT Lung in asymptomatic screening."

"Freenome...announced...that Pennsylvania-based Geisinger is joining as a study partner for the Sanderson Study, a study for the detection of multiple cancers that pairs multiomics with real-world data...The Sanderson Study encompasses both traditional and real-world data to generate evidence of clinical validation for certain high- and elevated-risk populations while also refining the platform’s cancer classification and risk prediction models."

"Freenome...presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans....Freenome and ADC Therapeutics have been applying this platform to investigate biological signatures associated with response to loncastuximab tesirine (lonca), a CD-19-directed antibody drug conjugate developed by ADC Therapeutics that is indicated for the treatment of adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines of therapy....The initial results are part of a larger ongoing collaboration between the companies. The findings presented at ASH show promise in identifying biomarkers associated with response to lonca and also suggested mechanisms of resistance seen in non-responders, which may inform future drug combination research."

"Freenome...announced...50 hospitals and community oncology practices across the United States have joined as clinical partners for its Vallania Study. The Vallania Study focuses on the detection of multiple cancers and launched earlier this year...The Vallania Study will focus on the refinement of Freenome’s multiomics platform, which is embedded with multi-cancer signatures to look for signals from several indications."

"Freenome...announced the launch of the Sanderson Study, the company’s latest study of its multiomics platform, in combination with real-world data to detect multiple cancers...The study will encompass both traditional and real-world data to generate evidence of clinical validation for certain high- and elevated-risk populations while also refining the platform’s cancer classification and risk prediction models. In addition, the Sanderson Study will build the necessary infrastructure to bridge the gap between clinical research and day-to-day clinical impact."

"Freenome...presented findings at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that demonstrate the clinical utility of detecting not just colorectal cancer (CRC), but also precancerous adenomas in a Medicare-aged cohort for tests that screen for CRC and multi-cancer early detection (MCED) tests that include CRC...The study findings are noteworthy because the prevalence of adenomas and asymptomatic CRC increases with age, and only 29% of those ages 65 and older are up to date on CRC screening."

“Oncimmune Holdings plc…announces it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute…Under this agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTagTM, to identify autoantibodies that can be predictive of patient response or associated with resistance to checkpoint inhibitors (‘CPIs’) and chemotherapy used in Dana-Farber led studies or therapy using atezolizumab, nivolumab, pembrolizumab, durvalumab and cisplatin-based chemotherapy. In addition, SeroTag will be used for identifying autoantibodies that can be predictive of immune-related adverse events ‘irAEs’) in response treatment. The project is scheduled to complete by the end of 2021.”

"Oncimmune Holdings plc...today announces that it has successfully agreed to acquire the intellectual property (IP) and distribution rights for the EarlyCDT® technology in the People's Republic of China (PRC) and Hong Kong (HK) from Genostics Company Limited (Genostics), allowing the Company to pursue the optimum route to market in this important territory...The Asia-specific lung panel has been used in a multi-centre study, previously announced on 10 May 2019, and which is now due to complete in China in H1 2021. Data from this study are intended to be used to support approval by the China National Medical Products Administration (NMPA) for the use of the Asia-specific lung cancer test in the PRC." "

"Oncimmune Holdings plc...today announces that it has signed a commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group ('Norfolk & Waveney'). Additionally, the Company has also signed a commercial contract to supply EarlyCDT Lung blood test into the NHS Lung Health Check Programmes in Wessex and Yorkshire as part of the iDx-LUNG evaluation programme. Following in-depth due diligence by the NHS, the Company has also been notified that The National Institute for Health and Care Excellence (NICE) has selected the EarlyCDT Lung blood test for Diagnostics Assessment Guidance...Under this commercial contract, Norfolk & Waveney will be evaluating the use of the EarlyCDT Lung blood test in a clinical setting."